- Home
- DAWN vs AMAL Comparison
DAWN vs AMAL Comparison
Compare DAWN & AMAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- AMAL
- Stock Information
- Founded
- DAWN 2018
- AMAL 1923
- Country
- DAWN United States
- AMAL United States
- Employees
- DAWN N/A
- AMAL N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- AMAL Commercial Banks
- Sector
- DAWN Health Care
- AMAL Finance
- Exchange
- DAWN Nasdaq
- AMAL Nasdaq
- Market Cap
- DAWN 1.3B
- AMAL 1.1B
- IPO Year
- DAWN 2021
- AMAL 2018
- Fundamental
- Price
- DAWN $12.79
- AMAL $33.66
- Analyst Decision
- DAWN Strong Buy
- AMAL Buy
- Analyst Count
- DAWN 7
- AMAL 4
- Target Price
- DAWN $36.17
- AMAL $37.13
- AVG Volume (30 Days)
- DAWN 1.0M
- AMAL 163.3K
- Earning Date
- DAWN 10-30-2024
- AMAL 01-23-2025
- Dividend Yield
- DAWN N/A
- AMAL 1.43%
- EPS Growth
- DAWN N/A
- AMAL 16.43
- EPS
- DAWN N/A
- AMAL 3.39
- Revenue
- DAWN $101,953,000.00
- AMAL $303,032,000.00
- Revenue This Year
- DAWN N/A
- AMAL N/A
- Revenue Next Year
- DAWN $36.10
- AMAL $4.24
- P/E Ratio
- DAWN N/A
- AMAL $9.92
- Revenue Growth
- DAWN N/A
- AMAL 12.76
- 52 Week Low
- DAWN $11.94
- AMAL $21.33
- 52 Week High
- DAWN $18.07
- AMAL $38.19
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- AMAL 38.89
- Support Level
- DAWN $12.26
- AMAL $34.47
- Resistance Level
- DAWN $12.81
- AMAL $35.60
- Average True Range (ATR)
- DAWN 0.52
- AMAL 0.94
- MACD
- DAWN -0.05
- AMAL -0.33
- Stochastic Oscillator
- DAWN 28.94
- AMAL 27.38
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.